

## **EISAI TO PRESENT LATEST DATA ON PERAMPANEL AND RUFINAMIDE AT 70TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the latest data on its antiepileptic drugs (AED) perampanel (product name: Fycompa<sup>®</sup>) and rufinamide (product name: Inovelon<sup>®</sup>, U.S. product name: BANZEL<sup>®</sup>) will be presented at the 70th American Epilepsy Society (AES) Annual Meeting to be held from December 2 to 6 in Houston in the United States.

For this year's AES meeting, poster presentations will be given on eight abstracts for perampanel which include the results of Phase II trials (Study 231, Study 233) of adjunctive perampanel in Japanese patients with refractory partial-onset seizures. Regarding rufinamide, a poster presentation will be given on the safety and cognitive development effects of adjunctive rufinamide in pediatric subjects with inadequately controlled Lennox-Gastaut Syndrome (LGS) from the final results of Study 303. Along with three poster presentations on health economics and outcome research, a total of 12 poster presentations will be given.

Perampanel is a first-

Major Poster Presentations for perampanel:

<b>Abstract number</b>	<b>Abstract title</b>
<b>Abstract number: #2.189</b> <i>Sunday December 4</i> <i>Poster presentation: 10:00-16:00</i> <i>Poster discussion: 12:00-14:00</i>	Evaluation of perampanel as monotherapy for focal seizures: experience from open-label extension studies

